Expired CME Article

Systemic Sclerosis and Malignancy: A Review of the Literature

Authors: Marc Wooten, MD,FACP, FACR

Abstract

Malignancy is associated with systemic sclerosis in between 3.6 and 10.7% of patients diagnosed with systemic sclerosis. The diagnosis of systemic sclerosis may occur before, concurrent with, or after the diagnosis of malignancy. All published reports of malignancy with systemic sclerosis are reviewed. Lung cancer is the most frequent type of cancer seen in patients with systemic sclerosis, followed by breast cancer. Risk factors for the development of malignancy in patients with systemic sclerosis are female gender, increased age, and diffuse systemic sclerosis. Autoantibodies such as anticentromere and antitopoisomerase I are inconsistent in their risk for developing malignancy. Vigilance is recommended in this group of patients based on their increased risk of developing cancer.


Key Points


* Malignancy is found in up to 10% of patients with systemic sclerosis. Risk factors for malignancy include female gender, increasing age, and the presence of diffuse systemic sclerosis.


* Lung cancer and breast cancer remain the most frequently reported types of malignancy in series dealing with systemic sclerosis and malignancy.


* Other common malignancies observed in systemic sclerosis patients include gastrointestinal, urogenital, and lymphatic malignancies.


* There is no consistent relationship reported between the presence of malignancy and typical autoantibodies followed in systemic sclerosis patients.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246–2255.
 
2. Allcock RJ, Forrest I, Corris PA, et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology 2004;43:596–602.
 
3. Duncan SC, Winkelmann RK. Cancer and scleroderma. Arch Dermatol 1979;115:950–955.
 
4. Hill CL, Nguyen AM, Roder D, et al. Risk of cancer in patients with scleroderma: a population-based cohort study. Ann Rheum Dis 2003;62:728–731.
 
5. Roumm AD, Medsger TA. Cancer and systemic sclerosis: an epidemiological study. Arthritis Rheum 1985;28:1336–1340.
 
6. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993;36:460–464.
 
7. Rosenthal AK, McLaughlin JK, Gridley G, et al. Incidence of cancer among patients with systemic sclerosis. Cancer 1995;76:910–914.
 
8. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005;52:2415–2424.
 
9. Derk CT, Rasheed M, Artlett CM, Jiminez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006;33:1113–1116.
 
10. Sakauchi F, Mori M, Ishikawa O, Endo H. [The association of systemic sclerosis with malignant neoplasms.] Nihon Rinsho Meneki Gakkai Kaishi 2004;27:402–406.
 
11. Derk CT, Arnett CM, Jimenez SA. Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study. Clin Rheumatol 2006;25:831–834.
 
12. Ardern-Jones MR, Black MM. Widespread morphoea following radiotherapy for carcinoma of the breast. Clin Exp Dermatol 2003;28:160–162.
 
13. Bleasel NR, Stapleton KM, Commens C, et al. Radiation-induced scleroderma in breast cancer patients. Australas J Dermatol 1999;40:99–102.
 
14. Davis DA, Cohen PR, McNeese MD, et al. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol 1996;35:923–927.
 
15. Wenzel J. Scleroderma and malignancy: mechanisms of interrelationship. Eur J Dermatol 2002;12:296–300.
 
16. Asano Y, Ihn H, Shikada J, et al. A case of peplomycin-induced scleroderma. Br J Dermatol 2004;150:1213–1214.
 
17. Battafarano DF, Zimmerman GC, Older SA, et al. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 1995;76:110–115.
 
18. De Angelis R, Bugatti L, Cerioni A, et al. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol 2003;22:49–52.
 
19. Farrant PB, Mortimer PS, Gore M. Scleroderma and the taxanes: is three really a link? Clin Exp Dermatol 2004;29:360–362.
 
20. Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 2001;19:197–200.
 
21. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682–686.
 
22. Villa AR, Kraus A, Jimenez-Corona A, et al. Malignant neoplasms in autoimmune rheumatic diseases: examination of the risk of developing a malignancy among five different rheumatic diseases in one institution. J Clin Rheumatol 2000;6:176–183.
 
23. Sakkas LI, Moore DI, Akritidis NC. Cancer in families with systemic sclerosis. Am J Med Sci 1995;310:223–225.
 
24. Roberts-Thomson PJ, Male DA, Walker JG, et al. Genomic instability in scleroderma. Asian Pac J Allergy Immunol 2004;22:153–158.
 
25. Kuwana M, Okasaki Y, Yasouka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet 2004;364:603–610.
 
26. Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine 2006;73:490–494.
 
27. Yang Y, Fujita J, Tokuda M, et al. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 2001;21:106–111.
 
28. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 2005;11:431–437.
 
29. Peters-Golden M, Wise RA, Hochberg M, et al. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985;12:1136–1139.
 
30. Talbott JH, Barrocas M. Carcinoma of the lung in progressive systemic sclerosis: a tabular review of the literature and a detailed report of the roentgenographic changes in two cases. Semin Arthritis Rheum 1980;9:191–217.
 
31. Kanaji N, Fujita J, Bandoh S, et al. Small cell lung cancer associated with systemic sclerosis. Intern Med 2005;44:315–318.
 
32. Forbes AM, Woodrow JC, Verbov JL, et al. Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol 1989;28:65–69.
 
33. Launay D, Le Berre R, Hatron PY, et al. Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 2004;23:516–522.
 
34. Scope A, Sadetzki S, Sidi Y, Barzilai A, et al. Breast cancer and scleroderma. Skin Med 2006;5:18–24.
 
35. Halpert RD, Laufer I, Thompson JJ, et al. Adenocarcinoma of the esophagus in patients with scleroderma. Am J Roentgenol 1983;140:927–930.
 
36. Katzka DA, Reynolds JC, Saul SH, et al. Barrett’s metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med 1987;82:46–52.
 
37. Wipff J, Allanore Y, Soussi F, et al. Prevalence of Barrett’s esophagus in systemic sclerosis. Arthritis Rheum 2005;52:2882–2888.
 
38. Boyeldieu D, Rouquette-Gally AM, Laugler A, et al. [Anticentromere antibody, CREST, and cancer.] Presse Med 1987;16:1924–1925.
 
39. Higuchi M, Horiuchi T, Ishibashi N, et al. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 2000;19:123–126.
 
40. Weiner ES, Earnshaw WC, Senecal JL, et al. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 1988;31:378–385.
 
41. Rothfield N, Kurtzman S, Vazgues-Abad D, et al. Association of anti-topoisomerase I with cancer. Arthritis Rheum 1992;35:724.
 
42. Kuwana M, Fujii T, Mimori T, et al. Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis: a report of two cases. Arthritis Rheum 1996;39:686–691.
 
43. Derk CT, Sakkas LI, Rasheed M, et al. Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. J Rheumatol 2003;30:1994–1996.
 
44. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2006 September 19; [epub ahead of print]. 2007;66:551–553.